ASCO 2024: MSD’s ADC shows efficacy in lung and breast tumours
MSD licenced the antibody-drug conjugate (ADC) therapy, sacituzumab tirumotecan, from China-based Sichuan Kelun-Biotech in 2022.
MSD licenced the antibody-drug conjugate (ADC) therapy, sacituzumab tirumotecan, from China-based Sichuan Kelun-Biotech in 2022.
The cost saving programme is expected to save the company approximately $1.5bn by 2027.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Sanofi enters partnership to enhance drug development using AI
UK clinical trials industry tackles recent changes in the sector
Rakovina expands collaborations to leverage AI platform
Biotechs must prioritise ethics to deter GenAI “bad actors”